Episurf Medical Receives CE Mark For Damage Assessment Tool

Stockholm, Sweden-based Episurf Medical AB has received the CE mark for its Epioscopy damage assessment tool. The device is an intelligent, patient specific decision support tool, generated through the company’s proprietary uiFidelity platform. With this new addition, Episurf Medical expands its product portfolio to include a stand-alone digital service aimed at surgeons and patients.

Epioscopy is an advanced clinical assessment tool intended to provide the physician with decision support information in the form of 3-D vizualizations of the segmented patient knee, visual marking of chondral and osteochondral lesions in the femoral part of the knee and a written assessment of structural deviations on the tibia, patella, meniscus and ACL. In the event that Episurf Medical’s implant solutions are considered to be an appropriate treatment option, a visualization of the implant/guide is added to the 3D image of the knee.

“We see the Epioscopy Damage Assessment Tool as a non-invasive complement to arthroscopy to enhance clinical decision making, with the ambition to further develop this product into a viable diagnostic tool,” said Rosemary Cunningham Thomas, CEO of Episurf Medical. “It is the company’s intention to also offer the Epioscopy service directly to prospective patients who are seeking treatment options following previously unsuccessful cartilage repair procedures.”

The global market for arthroscopic interventions is approximately 2 million per annum with a price range between $1,000-2,000. Given the consistent accuracy rate of Episurf Medical’s damage marking process, the Epioscopy tool aims to provide surgeons with a detailed patient specific assessment; the result being more cost effective care.

“Consistent customer feedback has helped the company understand the unique and significant value of our pre-surgical damage marking report as an intelligent planning guide which will be positioned to create new software as a service revenue streams“, added Thomas. “It’s also the view of Episurf Medical’s clinical advisory board that our pre-surgical assessment report offers a form of quality control that leads to appropriate procedure and patient selection, thereby improving clinical outcomes and patient satisfaction.”

Episurf Medical now has five patient specific products on the market which complement each other and help give people who suffer from joint pain a second chance to a live a normal and pain free life where previous treatments have failed.

“In the emerging field of early osteoarthritis, we believe a company that combines patient specific implants with sophisticated digital decision making tools is very attractive to surgeons, patients and investors. Advanced imaging techniques, combined with Episurf Medical’s core competency in assessing cartilage and bone damage, will enable the company to expand its platform into the screening and preventative health sector where early interventions can prevent future pain, improve mobility and greatly reduce health care costs associated with progressive, degenerative joint disease,” concluded Cunningham Thomas.

Episurf Medical makes technology to treat painful joint injuries.